Program
ercanetide
Its studies are mostly in Angelman Syndrome · Prader-Willi Syndrome, led by Neuren Pharmaceuticals.
Furthest: phase 3, since Nov 13, 20257 company-led studies, 2 open or runningNext primary completion: Oct 31, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Neuren Pharmaceuticals | 72 open or running | phase 3since Nov 13, 2025 | Apr 30, 2020 | Oct 31, 2027phase 3 · NCT07281079 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 30, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04379869 · 28 enrolled · Australia
- Aug 5, 20213 phase 2 studiesNCT05011851, NCT05025332, NCT05025241
- May 18, 2023Phase 2 study in Prader-Willi SyndromeNCT05879614 · United States
- Nov 13, 2025Phase 3 study in Telomeric 22q13 Monosomy SyndromeNCT07281079 · 160 planned · United States, Canada
- Mar 24, 2026Phase 3 study in Telomeric 22q13 Monosomy SyndromeNCT07593391 · 180 planned · United States
Ahead
- Oct 31, 2027Primary completion: phase 3 study in Telomeric 22q13 Monosomy SyndromeNCT07281079
- Oct 29, 2028Primary completion: phase 3 study in Telomeric 22q13 Monosomy SyndromeNCT07593391
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07593391Telomeric 22q13 Monosomy Syndrome · United States | 3 | Recruiting | Oct 29, 2028 | 180 |
| NCT07281079Telomeric 22q13 Monosomy Syndrome · United States, Canada | 3 | Recruiting | Oct 31, 2027 | 160 |
| NCT05879614Prader-Willi Syndrome · United States | 2 | Withdrawn | Jun 30, 2025 | 0 |
| NCT05025332Pitt-Hopkins syndrome · United States | 2 | Completed | Feb 27, 2024 | 28 |
| NCT05025241Telomeric 22q13 Monosomy Syndrome · United States | 2 | Completed | Nov 1, 2023 | 18 |
| NCT05011851Angelman Syndrome · Australia | 2 | Completed | May 13, 2024 | 17 |
| NCT04379869Healthy Volunteers · Australia | 1 | Completed | Feb 11, 2021 | 28 |
How it is read
Names in the registry
- “NNZ-2591”, 7 entries
Conditions, from the studies’ own filings
- Angelman Syndrome, 1 study
- Prader-Willi Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.